RxDoctor Payments Data

Joyce Thomas, MD

Internal Medicine · Trinity, FLNPI 1366410003

Payments from drug & device makers

$314in general payments, 2019–2025

Across 9 payments — averaging $34.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$125
  • Biohaven Pharmaceutical Holding Company Ltd.$80
  • Exact Sciences$58
  • Supernus Pharmaceuticals, Inc.$37
  • Amgen$14

What the payments were for

  • Food & beverage$30096%
  • Education$144%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$314 in reported general payments places this provider in the 45th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$181,160
Medicare patients
282
Services billed
3,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin141$146,898
OzempicSemaglutide103$128,975
TrulicityDulaglutide56$62,054
Repatha SureclickEvolocumab69$55,630
MounjaroTirzepatide48$53,177
EliquisApixaban49$47,510
XareltoRivaroxaban28$34,569
RybelsusSemaglutide25$28,704
JanuviaSitagliptin Phosphate35$28,636
Aimovig AutoinjectorErenumab-Aooe32$23,523
MyrbetriqMirabegron26$16,598
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$14,002
Breo ElliptaFluticasone/Vilanterol32$13,090
Tresiba Flextouch U-100Insulin Degludec15$11,879
Incruse ElliptaUmeclidinium Bromide21$9,567

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$125$16,59826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Trinity

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →